ArticleMethods in molecular biology (Clifton, N.J.)2026
Treating Immune Thrombotic Thrombocytopenic Purpura with Therapeutic Plasma Exchange.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic plasma exchange (TPE) has served as a first-line therapy for immune thrombotic thrombocytopenic purpura (iTTP) for decades, providing a rapid reduction in the causative anti-ADAMTS13 antibodies and replenishment of ADAMTS13 enzyme activity. Management of iTTP using TPE requires understanding the clinical and technical aspects of the procedure in order to provide safe and effective treatment. Furthermore, the apheresis practitioner must work within the context of a multidisciplinary team to individualize treatment to the patient and clinical circumstances. This chapter details the role of the apheresis consultant in assessing the patient, establishing treatment parameters, and managing treatment complications. The goal of the authors is to provide a blueprint for the stepwise process from differential diagnosis to disease resolution, including recommendations for developing a systematic treatment regimen, adjusting procedural settings to prevent and address complications, and modifying the treatment approach for unique patient populations.
Indexed as
Identifiers
41917366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.